Last edition
News about
Sartorius to Ramp Up Drug Discovery and Production with AI in Alliance with NVIDIA
Sartorius has extended its multidisciplinary partnership with NVIDIA to help enable the development of new and better therapies, combining Sartorius’ in-depth knowledge of life sciences and bioprocessing with NVIDIA’s AI-powered computing platforms and software.
The launch will be driven by its longstanding commercial partner, who have represented OrthAlign in the market since 2013 and supported over 68,000 OrthAlign cases.
Venous thromboembolism (VTE) is a significant medical condition characterized by the formation of blood clots within the deep venous system.
Avidity Biosciences Welcomes Simona Skerjanec to its Board of Directors
Avidity Biosciences, Inc. has strengthened its leadership with the appointment of Simona Skerjanec, M.Pharm, MBA to its board of directors.
Cipla Extends its Investment in Achira to Advance in PoC Diagnostic
Cipla Ltd. has signed definitive agreements for further investment of up to INR 26 crore in Optionally Convertible Preference Shares of Achira Labs Pvt. Ltd., in four tranches, subject to completion of certain milestones.
CASI Pharmaceuticals Advances CID-103 into Clinical Development for Chronic Immune Thrombocytopenia
CASI received a letter from the FDA indicating clearance for the study to proceed, signaling regulatory approval for the advancement of CID-103 into clinical trials.
Atraverse Medical Receives FDA Clearance for HOTWIRE Radiofrequency Guidewire
This device enables zero exchange left-heart access while also serving as a rail for catheter-based therapy systems.
Teva Names Matthew Shields as New Executive Vice President
Teva Pharmaceutical Industries Ltd. has appointed Matthew Shields as Executive Vice President of Teva Global Operations (TGO) under manufacturing and supply division
Lupin Secures ISO 14001 and ISO 45001 Certification for its Indian Sites and Centers
Lupin Ltd. has announced that all 12 of its manufacturing sites, its R&D Center, and its corporate office in India have completed rigorous audits and been certified by DNV for ISO 14001 — Environment Management Systems (EMS), and ISO 45001 — Occupational Health and Safety Management System (OHSMS).
Activities are currently underway to finalize the seamless Phase 2/3 master protocol design that will evaluate multiple investigational therapies for the treatment of pancreatic cancer. An intent of the study is to produce registration-enabling data.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy